Does positron emission tomography/computed tomography change management in colorectal cancer?

ANZ Journal of Surgery

Volumn 88, Issue 4, 2018, Pages E248-E251

  Falconer, Rachel ^a   Connor, Saxon ^a   Balasingam, Adrian ^a   Eglinton, Tim ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

colorectal cancer; liver metastases; positron emission tomography computed tomography

Indexed keywords

CLINICAL DECISION MAKING; COLON RESECTION; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; HUMAN; LIVER TUMOR; LUNG TUMOR; PATHOLOGY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDY; SECONDARY; TERTIARY CARE CENTER; TUMOR RECURRENCE;

CLINICAL DECISION-MAKING; COLECTOMY; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84995783958     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/ans.13798     Document Type: Article

References (23)

1. Ministry of Health. Cancer: Selected Sites 2010, 2011, 2012. [Cited 14 Feb 2014.] Available from URL: http://www.health.govt.nz/publication/cancer-selected-sites-2010-2011-2012
2. Cunningham R, Sarfati D, Hill S, Dennett E, O'Donnell A. Colon cancer management in New Zealand: 1996-2003. N. Z. Med. J. 2009; 122: 1–60.
3. Nickel M, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging and FDG PET and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have no previously undergone treatment. Radiology 2010; 257: 674–84.
4. Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhance 64-MDCT of the chest and abdomen. Am. J. Roentgenol. 2010; 194: 766–71.
5. O'Connor O, McDermott S, Slattery J, Sahani D, Blake MA. The use of PET-CT in the assessment of patients with colorectal carcinoma. Int. J. Surg. Oncol. 2011; 2011: 846512.
6. Christchurch Radiology Group. PET/CT Imaging Referral Form – Oncology. [Cited 12 Mar 2015.] Available from URL: http://www.christchurchradiology.co.nz/assets/files/PetCT-DHB-Refer-form2.pdf
7. Moulton C, Gu C, Law C et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases. A randomized clinic trial. JAMA 2014; 311: 1863–9.
8. National Ethics Advisory Committee. Ethical Guidelines for Observational Studies: Observational Research, Audits and Related Activities. Revised edition, July 2012. Wellington: Ministry of Health. [Cited 10 Oct 2015.] Available from URL: http://neac.health.govt.nz/streamlined-ethical-guidelines-health-and-disability-research
9. Fong Y, Forther J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastastic colorectal cancer. Analysis of 1001 consecutive cases. Ann. Surg. 1999; 203: 309.
10. Abdel-Nabi H, Doerr RI, Lamonica DM et al. Staging of primary colorectal carcinomas with fluorine-18-fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206: 755–60.
11. Arulampalam T, Francis D, Visvikis D, Taylor I, Ell P. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur. J. Surg. Oncol. 2004; 30: 286–91.
12. Desai D, Zevros E, Arnold M, Burak W, Mantil J, Martin E. Positron emission tomography affects surgical management in recurrrent colorectal cancer patients. Ann. Surg. Oncol. 2003; 10: 59–64.
13. Kalff V, Hicks R, Ware R, Hogg A, Binns D, McKenzie A. The clinical impact of 18 F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J. Nucl. Med. 2002; 43: 429–99.
14. Ruers TJ, Langenhoff BS, Neeleman N et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J. Clin. Oncol. 2002; 20: 388–95.
15. 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J. Nucl. Med. 2003; 44: 1797–803.
16. Selzner M, Hany T, Wildbrett P, McCormack L, Kadry Z, Clavien P. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann. Surg. 2004; 240: 1027–36.
17. Czernin J, Allen-Auerbach M, Schelbert H. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J. Nucl. Med. 2007; 48: 78S–88S.
18. Kuehl H, Veit P, Rosenbaum S, Bockisch A, Antoch G. Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. J. Nucl. Med. 2007; 48(Suppl 1): 45S–57S.
19. Kong G, Jackson C, Koh DM et al. The use of 18 F-FDG PET/CT in colorectal liver metastases: comparison with CT and liver MRI. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 1323–9.
20. Votrubova J, Belohlavek O, Jaruskova M et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur. J. Nucl. Med. Mol. Imaging 2006; 33: 779–84.
21. The Royal College of Physicians (RCP) and the Royal College of Radiologists (RCR). Evidence-Based Indications for the Use of PET-CT in the UK. London: RCP, RCR, 2013.
22. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer v.3.2013/Rectal Cancer v.4.2013. [Cited 17 Feb 2015.] Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf; http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf
23. Foo E, Moore T, Harris D, Yi M, Connor S. Long term outcomes for hepatic resection for colorectal liver metastases at a New Zealand tertiary level public hospital. ANZ J. Surg. 2016; 86: 285–8.